Clinical Cancer Research · 2018 · 60 citations · 28 references
PharmacyPharmacokineticsPharmacologyDose-response ModelingImmunopharmacologyImmunotherapyAntibody PharmacokineticsCancer ImmunotherapyPharmacodynamics Of ImmunotherapiesPharmacokinetics Of Monoclonal AntibodiesT Cell ActivationT Cell BiologyAcute Myeloid Leukemia TherapyCd3-directed Bispecific AntibodiesClonal Expansion Of LymphocytesMechanistic Pharmacokinetic-pharmacodynamic ModelsSequential Pharmacokinetic-pharmacodynamic ModelingSimultaneous Pharmacokinetic-pharmacodynamic ModelingT Cell Activation ModelingT Cell Clonal Expansion
Abstract Purpose: Flotetuzumab (MGD006 or S80880) is a bispecific molecule that recognizes CD3 and CD123 membrane proteins, redirecting T cells to kill CD123-expressing cells for the treatment of acute myeloid leukemia. In this study, we developed a mathematical model to characterize MGD006 exposure–response relationships and to assess the impact of its immunogenicity in cynomolgus monkeys. Experimental Design: Thirty-two animals received multiple escalating doses (100-300-600-1,000 ng/kg/day) via intravenous infusion continuously 4 days a week. The model reflects sequential binding of MGD006 to CD3 and CD123 receptors. Formation of the MGD006/CD3 complex was connected to total T cells undergoing trafficking, whereas the formation of the trimolecular complex results in T-cell activation and clonal expansion. Activated T cells were used to drive the peripheral depletion of CD123-positive cells. Anti-drug antibody development was linked to MGD006 disposition as an elimination pathway. Model validation was tested by predicting the activity of MGD006 in eight monkeys receiving continuous 7-day infusions. Results: MGD006 disposition and total T-cell and CD123-positive cell profiles were well characterized. Anti-drug antibody development led to the suppression of T-cell trafficking but did not systematically abolish CD123-positive cell depletion. Target cell depletion could persist after drug elimination owing to the self-proliferation of activated T cells generated during the first cycles. The model was externally validated with the 7-day infusion dosing schedule. Conclusions: A translational model was developed for MGD006 that features T-cell activation and expansion as a key driver of pharmacologic activity and provides a mechanistic quantitative platform to inform dosing strategies in ongoing clinical studies. Clin Cancer Res; 24(11); 2631–41. ©2018 AACR.
28
Population Dynamics of Immune Responses to Persistent Viruses
Martin A. Nowak, Charles R. M. Bangham · Science · 1996 · 1.3K citations